Autoimmune Disease Treatment Market Size was valued at USD 9.78 Billion in 2023. The Global Autoimmune Disease Treatment industry is projected to grow from USD 18.23 Billion in 2024 to USD 16.93 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.01% during the forecast period (2024 - 2032). The rising incidence of autoimmune conditions and regulatory framework and payment procedures improvement are the key market drivers enhancing the Autoimmune Disease Treatment market growth.
The key market drivers boosting the growth of the Autoimmune Disease Treatment market are the increasing prevalence of autoimmune disorders and the enhancement of the regulatory framework and payment procedures. The primary drivers of the Autoimmune Disease Treatment market are the rise in the prevalence of autoimmune diseases, the skyrocketing acceptance of autoimmune disease treatments, and the expansion of R&D efforts to supply the best medicines.
The presence of therapies, technological developments in screening processes, and medications in development all play a role. As the prevalence of autoimmune diseases rises, so too will the demand for therapies for these conditions. This bodes well for the growth of the Autoimmune Disease Treatment market.
Baricitinib, certolizumab, secukinumab, and other pipeline drugs are expected to have a significant impact on market growth due to their broad availability, technological developments in screening processes, and popularity in the market. As a result, these are also contributing to the expansion of the market for treatments for autoimmune diseases.
July 2023:Samsung Bioepis announced that it has released Hadlima, a biosimilar to Humira, in the United States in collaboration with Organon. Hadlima is licensed as both a prefilled pen (PFP) and a prefilled syringe (PFS) and comes in two different strengths: a low concentration (50 mg/ml) and a high concentration (100 mg/ml). The company is also working on a patient support program called "HADLIMA For You," which will provide patients with access to nurse coaches and other resources to help them through their treatment.
Med1 published an article from Kyverna Therapeutics, Inc. (Kyverna), a patient-centered biopharmaceutical firm at the clinical stage on KYV-101, the fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, administered to two progressive multiple sclerosis patients under a named patient program for severely sick adults unresponsive to other treatments. CAR T-cell therapy is simply the act of reprogramming certain types of immune cells in the body to attack B-cells. CD19 CAR T-cells have been specifically engineered to target CD19 surface protein found on various B cells implicated in some autoimmune diseases.
Rozanolixizumab-noli, a neonatal Fc receptor (FcRN)-binding humanized IgG4 monoclonal antibody that reduces circulating IgG levels, is injected subcutaneously as an infusion. According to UCB, a global biopharmaceutical company, the USA FDA approved Rozanolixizumab-noli under the trade name RYSTIGGO® for the treatment of Generalised Myasthenia Gravis (gMG) in adult patients who are Anti-acetylcholine receptor (AchR) and/or anti-muscle specific tyrosine kinase (MuSK) positive. It still remains the only FDA-approved treatment for gMG with both anti-AChR and anti-MuSK positivity which are two most common subtypes of gMG in adults.
Maven Clinic was announced by WellTheory as its global first employer partner for women’s and family health aimed at fifty million Americans who suffer from autoimmune diseases; it also happens to be the biggest virtual clinic globally. With effect from this day forward, employees at Maven Clinic will be able to access the WellTheory platform without any charges intended to solve their autoimmune symptoms via nutrition based on evidence and lifestyle coaching. Autoimmune and inflammatory conditions are over 100. They affect 15% of the workforce, while 78% of full-time workers reported decreased job performance due to it. The incidence of autoimmune diseases is pronouncedly higher among women and minority groups than men, where eighty percent of patients are women; there also exist disorders that occur sixteen times more frequently in females.
Kyverna Therapeutics, Inc., Kyverna being a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases, announced that its autologous full human CD19 chimeric antigen receptor (CAR) T-cell product candidate KYV-101 has been granted fast-track designation by the U.S. Food and Drug Administration (FDA) for treating myasthenia gravis (MG). Fast Track is a process that allows the FDA to rapidly develop and review drugs intended to address unmet medical needs in the context of severe or life-threatening conditions.
The growth in autoimmune disease incidence, the exploding adoption of autoimmune disease therapeutics, and the expansion of R&D efforts to provide the best medicines are the main drivers of the Autoimmune Disease Treatment market. In addition, the availability of therapeutics, technological advancements in screening procedures, and the presence of pipeline drugs like tocilizumab, baricitinib, secukinumab, etanercept, elotuzumab, abatacept, apremilast, PF-06438179, golimumab, ustekinumab, certolizumab, and tofacitinib The Autoimmune Disease Treatment market size are expected to increase as autoimmune illnesses are becoming more common and as people become more aware of the need to use treatments for them.
Market expansion is anticipated to be accelerated by the rise in autoimmune diseases. According to the Atlas of Multiple Sclerosis Report from 2020, more than 2.8 million individuals live with multiple sclerosis globally, including around 1 million in the United States. The prevalence of autoimmune diseases is rising, which is a worry for the countries of Europe. According to the Multiple Sclerosis Trust, there will be 2.5 million persons with multiple sclerosis globally in 2020, with Europe having the highest frequency. Multiple sclerosis affects women more commonly than it does men. Multiple sclerosis affects women more commonly than it does men. Two million people have rheumatoid arthritis, whereas 2% to 3% of the general population are considered to have psoriasis, one of the most common autoimmune conditions. The growing awareness of autoimmune illnesses due to initiatives for research, education, support, and advocacy is one of the main factors influencing rising usage rates.
Every year, March is designated Autoimmune Disease Awareness Month by the American Autoimmune Related Disease Association (AARDA), an organization dedicated to eliminating autoimmune diseases, alleviating suffering, and the socioeconomic effects of autoimmunity (ADAM). In February 2021, the American Kidney Fund (AKF) introduced a new patient-focused education and awareness campaign on the kidney disease lupus nephritis. The AKF campaign gave lupus patients the crucial knowledge they require on lupus nephritis's signs, prognosis, and therapy. GlaxoSmithKline plc provided grant money for the production of the AKF advertisement. Similar to this, Scipher Medicine and Ventegra Inc. partnered in September 2021. Under the partnership, Ventegra can give its clients access to Scipher's PrismRA liquid molecular signature test, which assists in selecting the most effective medication for those with rheumatoid arthritis (RA). Thus, the reasons above would be anticipated to raise the Autoimmune Disease Treatment market CAGR.
The widespread availability of treatments, technical advancements in screening processes, and the prominence of pipeline pharmaceuticals like baricitinib, certolizumab, secukinumab, and others are all predicted to impact the market's expansion positively. Therefore,these are the other factors driving the Autoimmune Disease Treatment market revenue growth.
The Autoimmune Disease Treatment market segmentation, based on Disease Type, includes Localized and Systemic. The Systemic segment held the majority share in 2022, contributing to around ~65-67% of the Autoimmune Disease Treatment market revenue.This significant market share results from the systemic autoimmune illnesses' sharp increase in prevalence, correlated with an increase in morbidity and death rates.
The Autoimmune Disease Treatment market segmentation, based on type, includes Elisa, Dot Blot, Agglutination, and Others. The Elisa segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Hence, rising of autoimmune diseases will positively impact market growth. The market for enzyme-linked immunosorbent assays (ELISA) is expected to grow over the next years due to the developing oncology applications of ELISA, the rising incidence of infectious illnesses and cancer, and the rising need for reasonably priced diagnostic equipment. Researchers and students frequently utilize ELISA at biotechnology academic institutions and research labs, which will drive the Autoimmune Disease Treatment market growth.
Therapeutic Products have bifurcated the Autoimmune Disease Treatment market data into Drugs, Monitoring Equipment. The Drug segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. Biologics, immunosuppressants, anti-inflammatory medicines, corticosteroids, and non-steroidal anti-inflammatory pharmaceuticals are further divided into the drug sector. NSAID, DMARD, biologic DMARD, and 5-ASA are some of the most popular generic medications; Avonex, Rebif, Copaxone, and Betaseron are some of the most popular branded medications. Because autoimmune disorders are chronic and common, the markets for medications, therapies, and monitoring are expanding.
Figure 1: Autoimmune Disease Treatment Market, by Disease type, 2023 & 2032 (USD Billion) 
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
September 2022: Zenas BioPharma, which was licensed from Xencor less than a year ago, secured $118 million in a series B round of funding in November 2022 so that it could focus on developing immune-based treatments. The equity funding will be used by the Massachusetts biotech to initiate a global phase 3 trial for lead candidate obexelimab before the end of the year. Patients with IgG4-related disease, a chronic fibroinflammatory disorder that can manifest in a variety of ways, are being studied to determine the efficacy of the bispecific antibody. With this fresh capital, Zenas will be able to go forward with clinical development of its other autoimmune disease initiatives in 2023.
July 2023: Celltrion Healthcare also announced the Monday, July 2023 release of Yuflyma, its Humira biosimilar, in the United States. Yuflyma comes in auto-injector and PFS formats, and its concentration is rather high. Since Celltrion must factor in additional rebates and discount expenses, the final selling price of Yuflyma will be different from the stated WAC price. The company is also introducing a healthcare provider and patient assistance program to reduce the financial burden of co-payments and product costs. In order to increase the prescribing of Yuflym, the business intends to conduct a number of patient-facing marketing initiatives around the United States, utilizing the commercial capabilities of local organizations.
Autoimmune Disease Treatment Regional Insights
By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America Autoimmune Disease Treatment market accounted for USD 0.61 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. According to the Autoimmune Registry, 2021, the United States has the greatest prevalence of autoimmune diseases (AD), with 15 to 30 million persons afflicted. To promote research on autoimmune disorders, the National Institutes of Health (NIH) offered two funding opportunities in March 2021 under the program Advancing Medicines Partnership: Autoimmune and Immune-Mediated Diseases (AMP AIM).
Figure 2: AUTOIMMUNE DISEASE TREATMENT MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Autoimmune Disease Treatment industry is second in the market for treating autoimmune diseases. The European market would function more likely because of the financial assistance the government agencies offered for R & D and changes in healthcare reimbursement rules. Further, the Germany Autoimmune Disease Treatment market held the largest market share, and the UK Autoimmune Disease Treatment market was the fastest-growing market in the European Region.
Asia Pacific is the Region with the fastest expanding Autoimmune Disease Treatment market for treating autoimmune diseases due to its large patient base and improving healthcare technologies. Also, it has been observed that healthcare costs are growing across the Asia Pacific. Moreover, the China Autoimmune Disease Treatment market held the largest market share, and the India Autoimmune Disease Treatment market was the fastest-growing market in the Asia-Pacific region.
Autoimmune Disease Treatment Key Market Players & Competitive Insights
Leading market players are investing a lot of money in R&D to expand their product portfolios, which will spur further market growth for Autoimmune Disease Treatment. With significant industry changes, including new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations, market development are also undertaking various strategic activities to expand its presence. In order to grow and remain in a market that is becoming more and more competitive, Autoimmune Disease Treatment industry competitors must provide affordable products.
Manufacturing locally to cut operational costs is one of the main business tactics the Autoimmune Disease Treatment industry uses to serve customers and increase the market sector. The Autoimmune Disease Treatment industry has recently given medicine some of the most important advantages. The Autoimmune Disease Treatment markets major players such as Abbott Laboratories, Amgen Inc., Genentech Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bio-Rad, Chugai Pharmaceutical Co. Ltd., Danaher, Elan Corporation Plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, HYCOR Biomedical, Johnson & Johnson Inc., Merck & Co. Inc., and others are working on expanding the market demand by investing in research and development activities.
Pfizer Inc. is a worldwide pharmaceutical and biotechnology company with its main offices in Manhattan, New York City, on 42nd Street. Priovant Therapeutics, founded by Roivant Sciences and Pfizer in June 2022, aims to create and market cutting-edge treatments for autoimmune disorders with the highest morbidity and fatality rates.
By providing top-notch biosimilars to roughly 110 nations, Celltrion Healthcare has emerged as the world's leading biologics firm. In Brazil, the biggest pharmaceutical market in Latin America, Celltrion Healthcare announced that its bid for Remsima, a biosimilar of AbbVie's Humira medication for autoimmune diseases, was successful. Also, the business disclosed receiving orders from 12 provincial governments in bidding.
Key Companies in the Autoimmune Disease Treatment market include
February 2022:Revolo Biotherapeutics has been permitted by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to start two Phase II trials of its potential autoimmune disease treatment "1805".
November 2020:To develop a novel program for those with rheumatoid arthritis, Myriad Genetics, Inc. and Integrated Prescription Management (IPM) reached an understanding (RA).
Anterior Interbody Fusion
Anterior Cervical Fusion
Posterior Fusion
Others
Metal
Polymer
Others
Minimally Invasive Spine Surgery
Open Spine Surgery
Orthopedic Clinics
Multispecialty Hospitals
Neurology Clinics
Others
Autoimmune Disease Treatment Regional Outlook
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 9.78 billion |
| Market Size 2024 | USD 18.23 billion |
| Market Size 2032 | USD 19.63 billion |
| Compound Annual Growth Rate (CAGR) | 7.01% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Operating Platforms, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Abbott Laboratories, Amgen Inc., Genentech Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bio-Rad, Chugai Pharmaceutical Co. Ltd., Danaher, Elan Corporation Plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, HYCOR Biomedical, Johnson & Johnson Inc., Merck & Co. Inc. |
| Key Market Opportunities | Technological advancements and unmet medical needs |
| Key Market Dynamics | Rising incidence of autoimmune conditions Regulatory framework and payment procedures improvement |
Frequently Asked Questions (FAQ) :
The Autoimmune Disease Treatment market size was valued at USD 9.78 Billion in 2023.
The Autoimmune Disease Treatment market is projected to grow at a CAGR of 7.01% during the forecast period, 2024-2032.
North America had the largest share in the Autoimmune Disease Treatment market.
The key players in the Autoimmune Disease Treatment market are Abbott Laboratories, Amgen Inc., Genentech Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bio-Rad, Chugai Pharmaceutical Co. Ltd., Danaher, Elan Corporation Plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, HYCOR Biomedical, Johnson & Johnson Inc., Merck & Co. Inc.
The systemic Autoimmune Disease Treatment category dominated the market in 2022.
The drugs had the largest share in the Autoimmune Disease Treatment market.
The market is expected to exhibit a strong 7.01% CAGR over the forecast period from 2024-2032.
The growing prevalence of autoimmune diseases is the major drive for the market.
The Americas dominate the global autoimmune disease treatment market.
Leading players in the autoimmune disease treatment market include Abbott, Amgen, and Bayer, among others.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
